Press Release

Daiichi Pharmaceutical Transfers Manufacturing Rights for Norinyl T28 Contraceptive to KAKEN PHARMACEUTICALFebruary 24, 2000

 Daiichi Pharmaceutical Co., Ltd. (headquarters: Chuo-ku, Tokyo, president: Kiyoshi Morita), announced today that it has agreed to transfer manufacturing rights for Norinyl T28, a low-dose oral contraceptive, to KAKEN PHARMACEUTICAL Co., Ltd. (headquarters: Bunkyo-ku, Tokyo, president: Shiro Inui).

 

 Daiichi Pharmaceutical began manufacturing Norinyl T28 after receiving manufacturing approval on June 16, 1999. Under a sales agreement, KAKEN PHARMACEUTICAL launched Norinyl T28 in November.

 

 The new agreement transfers all manufacturing, sales, and post-marketing surveillance activities regarding Norinyl T28 from Daiichi Pharmaceutical to KAKEN PHARMACEUTICAL.

Back to list